Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received a consensus rating of “Moderate Buy” from the twelve analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $25.4444.

Several analysts have recently weighed in on ELAN shares. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. UBS Group upped their target price on Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. Finally, Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th.

Insider Activity

In other Elanco Animal Health news, insider Rajeev A. Modi bought 4,500 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the transaction, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Robert M. Vanhimbergen bought 6,950 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were bought at an average cost of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares in the company, valued at approximately $2,688,402.12. The trade was a 5.93% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 43,450 shares of company stock valued at $937,883. 0.89% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SJS Investment Consulting Inc. lifted its position in shares of Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares during the period. Huntington National Bank boosted its position in Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares during the last quarter. Root Financial Partners LLC increased its stake in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares during the period. Whittier Trust Co. of Nevada Inc. raised its position in Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after purchasing an additional 951 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.5%

Shares of Elanco Animal Health stock opened at $25.15 on Friday. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $26.08. The stock has a fifty day moving average price of $23.46 and a 200-day moving average price of $21.01. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The firm has a market cap of $12.50 billion, a PE ratio of 419.30, a P/E/G ratio of 3.71 and a beta of 1.87.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.